Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
NCT01474772
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Men or women who are at least 18 years old.
- Diagnosis of painful diabetic peripheral neuropathy.
- Pain on walking.
- Inability to walk 50 feet on a flat surface.
- Pain on walking due to conditions other than diabetic peripheral neuropathy.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Mobile, Alabama
- Goodyear, Arizona
- Litchfield Park, Arizona
- Little Rock, Arkansas
- Fullerton, California
- Irvine, California
- La Jolla, California
- Boulder, Colorado
- Atlantis, Florida
- Bradenton, Florida
- Clearwater, Florida
- Destin, Florida
- Fort Walton Beach, Florida
- Hallandale Beach, Florida
- Palm Beach Gardens, Florida
- Sunrise, Florida
- West Palm Beach, Florida
- Decatur, Georgia
- Fort Wayne, Indiana
- Greenfield, Indiana
- Greenfirld, Indiana
- Lenexa, Kansas
- Hollywood, Maryland
- Ann Arbor, Michigan
- Nixa, Missouri
- Springfield, Missouri
- Missoula, Montana
- Asheville, North Carolina
- Dayton, Ohio
- Dayton, Ohio
- Toledo, Ohio
- Oklahoma City, Oklahoma
- Oklahoma, Oklahoma
- Greensburg, Pennsylvania
- Orangeburg, South Carolina
- Houston, Texas
- San Antonio, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- West Jordan, Utah
- Goodyear, Arizona
- Phoenix, Arizona
- Fresno, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Brandon, Florida
- Brandon, Florida
- Clearwater, Florida
- North Palm Beach, Florida
- Tampa, Florida
- West Palm Beach, Florida
- Winter Haven, Florida
- Columbus, Georgia
- Evansville, Indiana
- Wichita, Kansas
- Omaha, Nebraska
- Henderson, Nevada
- Las Vegas, Nevada
- Las Vegas, Nevada
- New York, New York
- Toledo, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Medford, Oregon
- Portland, Oregon
- Portland, Oregon
- Altoona, Pennsylvania
- Duncansville, Pennsylvania
- Pawtucket, Rhode Island
- Orangeburg, South Carolina
- Houston, Texas
- Houston, Texas
- Norfolk, Virginia
- Brno-Bystrc,
- Praha 10,
- Praha 5,
- Johannesburg, Gauteng
- Lenasia, Gauteng
- Durban, Kwa-Zulu Natal
- Richards Bay,
- Falkoping,
- Malmo,
- Stockholm,
- Stockholm,
- Hot Springs, Arkansas
- La Jolla, California
- Torrance, California
- Torrance, California
- Denver, Colorado
- Ocala, Florida
- Ocala, Florida
- Palm Beach Gardens, Florida
- Sunrise, Florida
- West Palm Beach, Florida
- West Palm Beach, Florida
- Boston, Massachusetts
- Omaha, Nebraska
- Omaha, Nebraska
- Las Vegas, Nevada
- Englewood, New Jersey
- New Brunswick, New Jersey
- Albany, New York
- Rochester, New York
- Rochester, New York
- Greenville, North Carolina
- Toledo, Ohio
- Duncansville, Pennsylvania
- Dallas, Texas
- Dallas, Texas
- Houston, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN) | |||
Official Title ICMJE | A Phase 3b Multicenter, Double-blind, Randomized, Placebo-controlled Cross-over Efficacy And Safety Study Of Pregabalin In The Treatment Of Patients With Painful Diabetic Peripheral Neuropathy And Pain On Walking | |||
Brief Summary | The intent of this study is to treat subjects with painful Diabetic Peripheral Neuropathy (DPN) who also have pain on walking and to determine whether or not pregabalin demonstrates improvement relative to placebo on the following: reducing DPN pain, reducing pain on walking, and providing other benefits associated with daily activities and quality of life. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Diabetic Peripheral Neuropathy | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Huffman C, Stacey BR, Tuchman M, Burbridge C, Li C, Parsons B, Pauer L, Scavone JM, Behar R, Yurkewicz L. Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking. Clin J Pain. 2015 Nov;31(11):946-58. doi: 10.1097/AJP.0000000000000198. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 217 | |||
Original Estimated Enrollment ICMJE | 175 | |||
Actual Study Completion Date ICMJE | July 2013 | |||
Actual Primary Completion Date | July 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Czech Republic, South Africa, Sweden, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT01474772 | |||
Other Study ID Numbers ICMJE | A0081269 2011-003266-32 ( EudraCT Number ) | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2014 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |